A Future without Heavy Metal Poisoning

About Us Our Science

At HOPO Therapeutics, we are working towards a future free from the damage caused by lead poisoning. About 1 in 3 children - up to 800 million globally - have dangerously high blood lead levels. Across the world, contaminated drinking water, lead-based paint, and many other sources of exposure silently poison children in their homes. Women who have been exposed to lead also pass the toxin on during pregnancy, causing irreversible damage to children’s brains and bodies that persists throughout their lives. This “Silent Epidemic” is an urgent and transgenerational issue in women’s and children’s health, and a devastating example of health inequity.

HOPO Therapeutics develops best-in-class pharmaceuticals for the treatment of heavy metal contamination. We are developing formulations of our flagship active pharmaceutical ingredient, 3,4,3-LI(1,2-HOPO), for the treatment of lead poisoning, as well as exposure to other toxic environmental contaminants like cadmium, gadolinium deposited in the body after exposure to MRI contrast agents, and protection from radioactive elements like plutonium and americium in a nuclear disaster.

Our class-leading heavy metal chelating agents have been optimized for maximum efficacy, safety, and oral availability, and are effective for both the treatment and prevention of heavy metal deposition. More about our science.

HOPO-001, an oral formulation of our lead compound, has been granted Investigational New Drug status by the FDA, and we anticipate a first-in-human Phase I clinical trial to begin in 2022.

Recent News

New strategic direction for the company announced

Co-founder and CEO Julian Rees, Ph.D. discusses a shift in HOPO’s focus area in last week’s newsletter READ

HOPO Therapeutics joins Pad-13 program at Berkeley SkyDeck

The UC Berkeley-based startup incubator / accelerator provides a vast network of resources, contacts, and guidance to help us achieve our mission

HOPO Therapeutics team awarded 2021 Bakar Fellowship from UC Berkeley

Rebecca Abergel, Ph.D. and Julian Rees, Ph.D. have received a Bakar Fellowship from UC Berkeley to advance the commercial development of our heavy metal chelator 3,4,3,-LI(1,2-HOPO)

Rebecca Abergel granted tenure

Huge congratulations to co-founder Rebecca Abergel, Ph.D. on her promotion to Associate Professor with tenure!

Letter to stakeholders from CEO Julian Rees

Co-founder and CEO Julian Rees, Ph.D. sent a letter yesterday with important company news and updates - you can read it here. Join our mailing list to stay on top of more news!


Important Notice About Obtaining HOPO

General Inquiries

HOPO Therapeutics, Inc.
+1 (510) 239 3180


Specific Inquiries

News & Media: media@hopotx.com
Investors: investors@hopotx.com
Partnerships: partnerships@hopotx.com
Legal: legal@hopotx.com
Careers: careers@hopotx.com


Mailing List

Interested in staying up to date? Join our mailing list! We send periodic updates on our research and development progress, and other outside sources related to heavy metal poisoning that we find especially impactful.